FGF2 and prostate carcinoma: Figure 3a presents results of the proof of principal experiment in which LNCap and NBTII cell lines were used as a positive control for PSA and FGF2 secretion, respectively. Figure 3b displays PSA immunospots representing protein fingerprints of single viable PSA-secreting cells defined as functional CTCs obtained from the blood of prostate cancer patients.